Dutch privately-held life sciences company Cristal Therapeutics has appointed Jeroen Tonnar as new chief business officer responsible for business development, partnering and licensing activities. 21 April 2015
Danish CNS specialist Lundbeck has entered into an exclusive worldwide license agreement with privately-held US biotech start-up Ovid Therapeutics for gaboxadol. 19 April 2015
Germany’s Merck KGaA has appointed Udit Batra to head the combined life science business following the pending acquisition of US life science company Sigma-Aldrich. 14 April 2015
Takeda Pharmaceuticals USA, the US subsidiary of Japan’s largest drugmaker Takeda, has appointed Ramona Sequeira as president of the US business unit. 13 April 2015
EMD Serono, the US biopharma subsidiary of Germany’s Merck KGaA has appointed Frederick Munschauer as vice president of medical affairs, neurology and immunology. 2 April 2015
UK-based stem cell therapy company ReNeuron is making changes to its board and senior management as it prepares for the next phase of development. 2 April 2015
Konstantinos (Kostas) Kosmatopoulos, a founder of anti-tumor immunotherapy specialist Vaxon Biotech, has become chief executive of the company. 30 March 2015
Japanese pharma company Otsuka has announced that its current vice chairman and representative director Ichiro Otsuka is now chairman and representative director. 30 March 2015
USA-based pharma company Inovio Pharmaceuticals has appointed Scott White as vice president of clinical development in infectious diseases. 18 March 2015
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024